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High-Risk Plaques*
Pedro R. Moreno, MDP laque rupture, deﬁned as direct exposure ofthe necrotic core to ﬂowing blood, is a majorcause of arterial thrombosis, acute myocardial
infarction, and sudden coronary death. A highly
thrombogenic necrotic core is separated from the
lumen by a thin ﬁbrous cap that is the last barrier be-
tween stability and atherothrombosis. Also known as
the “Achilles heel” of plaque, this ﬁbrous cap is
composed mostly of interstitial collagen and normally
possesses mechanical stiffness that is greater than
that of the adjacent intima. However, the presence
of foam-cell macrophages, enzymatic degradation
of collagen by matrix metalloproteinases (MMPs),
microcalciﬁcations, and nonload-bearing lipid pools
can lead to local thinning known as thin-cap ﬁbroa-
theroma (1), increasing the risk of plaque rupture
and future coronary events (2,3).
The good news: statin therapy is associated with
thickening of the ﬁbrous cap (4–8) and aggressive
statin therapy can reduce atheroma volume (9,10) and
lipid core burden index (11). Additionally, statins are
associated with signiﬁcant reductions in macrophage
inﬁltration, MMPs, tissue factor expression, and
plaque neovascularization, as well as increases in
collagen and smooth muscle cells in experimental
animals and humans (12–14).SEE PAGE 2207In this issue of the Journal, Komukai et al. (15)
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produces the near-infrared catheter.cap thickness (FCT) in 70 patients who, after success-
ful percutaneous coronary intervention (PCI), were
randomized to atorvastatin 5 mg/day or 20 mg/day,
in a prospective, open-labeled study. Nonculprit
lesions with intermediate severity (30% to 70% ste-
nosis by angiography), proximal to the PCI site,
were evaluated at baseline and 1-year follow-up
using optical coherence tomography (OCT). The main
objective was to quantify changes of FCT at the
thinnest segment, also known asminimal FCT (mFCT).
Macrophage accumulation, lipid arc, lipid length, and
minimal lumen area also were measured, with se-
rum samples of plasma lipoproteins, high-sensitivity
C-reactive protein (hs-CRP), interleukin (IL)-6, and
MMP-9 collected for comparison. Only patients with
plasma levels of low-density lipoprotein cholesterol
(LDL-C) >100 mg/dl were included in the study.
Images were collected using the time-domain OCT,
which requires balloon occlusion of the vessel to
remove blood from the ﬁeld of view. Sample size
calculation was based on an expected mFCT differ-
ence of 100 mm between the 2 groups. However,
this number was lower than the expected SD of the
sample, as established by previous studies (4).
Baseline characteristics showed higher numerical
values of LDL-C, malondialdehyde-modiﬁed-LDL,
hs-CRP, IL-6, MMP-9, and lower triglyceride values in
the atorvastatin 20 mg/day group compared with the
5-mg/day cohort. Furthermore, baseline OCT values
also showed higher numerical values for lipid arc,
lipid length, and lesion length in the higher dose of
atorvastatin group. Importantly, mFCT was 10%
lower in the patients receiving the higher dose of
atorvastatin. The authors do not provide statistical
comparisons for these baseline discrepancies, al-
though they do state that the 2 groups were well
matched at baseline.
At 1-year follow-up, 60 patients (86%) were
available for repeat OCT analysis. Measurements
FIGURE 1 Evolving Concepts in Macrophage Cholesterol and Iron Metabolism
After ingestion of erythrocytes, red cell membrane releases free cholesterol, activating the
liver X receptor (LXR). This pathway induces cholesterol export through ABCA1 (mem-
brane), handling cholesterol to high-density lipoprotein (HDL). Simultaneously, heme
stress by free hemoglobin (Hb) also activates LXR, inducing heme oxygenase (HO)-1 with
the production of ferritin. This pathway is in charge of iron metabolism and handling
(19,32,33). IL4 ¼ interleukin 4; MR ¼ mannose receptor; Ox ¼ oxidized.
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2219comparing changes in mFCT from baseline were per-
formed within the target plaque, but not always at the
corresponding site. The authors stated that the OCT
system could not perfectly detect the exact concor-
dant sites in the 2 pullbacks on the same vessel.
Despite this important caveat, the percentage of in-
crease in mFCT was statistically higher in patients
receiving 20 mg/day of atorvastatin (69%) compared
with those taking 5 mg/day (17%). Considering the
nonparametric data distribution, the authors com-
pared median  25th to 75th interquartile range.
However, even in the high-dose statin group, the
actual increase in mFCT was below the 25th inter-
quartile range, raising questions regarding objective
interpretation.
When analyzing other measurements at the plaque
level, both doses were associated with reductions in
lipid length, lipid arc, and macrophage grade, but
patients on higher dose statin therapy did exhibit a
higher percentage of reduction in the latter 2 param-
eters. Similarly, at the systemic level, both therapies
were associated with reductions in total cholesterol,
LDL-C, hs-CRP, IL-6, and MMP-9, but again, the per-
centage of reduction in LDL-C and MMP-9 was greater
with atorvastatin 20 mg/day. Importantly, neither
group showed changes in HDL-cholesterol plasma
levels.
In exploring possible mechanistic pathways, the
investigators reported multiple associations between
these systemic biomarkers and the percentage of
change in ﬁbrous cap thickness and in macrophage
grade. Yet the mean differences between the groups
for many of these variables can produce the appear-
ance of a correlation that does not exist, obscure a
correlation, or even reverse the direction. Findings
based on these circumstances violate the assumption
of independence of observation because the in-
dividuals are not sampled independently from a sin-
gle population. Consequently, these correlations do
not provide evidence of an association among
variables. This is a variant of Simpson’s paradox.
Although the authors acknowledged this limitation,
this ﬂaw must be clariﬁed for potential miscon-
ceptions suggested by the correlations presented.
Despite these signiﬁcant limitations, the ﬁndings
are consistent with previous reports from this group
and others showing improvements in mFCT and lipid
core reductions with aggressive statin therapy (4–6).
Considering that plaques with the thinnest caps were
the ones showing increased FCT on statin therapy (4),
baseline differences in mFCT create the potential for
selection bias. Following the same pathway, baseline
differences in the lipid arc also could contribute to
the reported changes, considering that plaques withthe largest lipid core burden index exhibited the
greatest reductions after aggressive statin therapy
(16). Although a dose-dependent response suggests a
mechanistic pathway for statins in plaque regression,
the speciﬁc mechanisms were not elucidated in the
present study. However, the data suggest that plaque
regression occurs after the resolution of inﬂamma-
tion, both at the plaque level and at the systemic
level.
RESOLUTION OF INFLAMMATION AND PLAQUE
REGRESSION. Monocyte-derived macrophages can
differentiate into those that promote inﬂammation,
which are referred to as classically activated (M1)
macrophages, and those that promote resolution of
inﬂammation and collagen synthesis, also referred to
alternatively as activated (M2) macrophages (17).
Supported by TH1 lymphocytes (hence the name M1
macrophages), proinﬂammatory phagocytes are
associated with insulin resistance, and secretion of
matrix metalloproteinases, thinning of ﬁbrous cap,
destruction of thin-wall microvessels, intraplaque
hemorrhage, plaque rupture, and thrombosis. In
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2220contrast, M2 macrophages are supported by Th2
lymphocytes and are associated with insulin sensi-
tivity, removal of apoptotic bodies from the plaque
(efferocytosis), and collagen synthesis by trans-
forming growth factor beta–mediated activity (17).
More recently, a new macrophage subtype respon-
sible for resolution of intraplaque hemorrhage and
iron handling were characterized and are named as
M(Hb) (18) and/or M(Hem) (19).
Resolution of inﬂammation plays a crucial role in
plaque regression (20). Macrophage plaque egression
through perivascular lymphatic system is dependent
on chemokine receptor 7 (CCR7) (21). The molecular
mechanisms involved the liver X receptor (LXR), also
responsible for the HDL-dependent reverse choles-
terol transport (22,23). Atorvastatin and rosuvastatin
promoted macrophage egression, increasing tran-
scriptional activity and chromatin organization at the
CCR7 promoter (24). Local proliferation of M2 mac-
rophages, independent of CCR7, may also play a role,
as documented in the ApoE encoding adenoviral
vector model (25). In addition to macrophage effer-
ocytosis, plaque regression is intimately related to
the HDL pathway. However, human studies doc-
umenting plaque regression show minimal or no
changes in HDL-C plasma levels. Furthermore, suc-
cessful pharmacologic efforts to increase HDL-C
(up to 70%) showed no beneﬁt and possible harm topatients (26,27). Rather than HDL-C plasma levels, it
is the HDL function through ApoA1 that likely drives
the beneﬁts of HDL (28,29).
Finally, resolution of inﬂammation also involves
removal of Hb, haptoglobin, and iron after intraplaque
hemorrhage (30,31).This pathway may be intimately
ligated to the reverse cholesterol transport pathway,
through the LXR (Figure 1) (32,33). The LXRa was re-
ported to dominate the M(Hb) macrophage (18),
whereas LXRb is required for iron-handling capacity in
the Mhem macrophage (19). Cholesterol removal and
iron metabolism may interact within the same
macrophage (19,32,33). Teleologically, this provides a
link between lipid metabolism, inﬂammation, macro-
phage homeostasis, and intraplaque hemorrhage.
Once more, statins are associated with resolution of
inﬂammation, collagen production, and bolstering cap
thickness to reduce the “Achilles heel” of high risk.
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